Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial

Cardiovascular Drugs and Therapy

Volumn 30, Issue 2, 2016, Pages 169-175

  Liou, Kevin ^a,b   Jepson, Nigel ^a,b   Buckley, Nicolas ^b,c   Chen, Vivien ^b,d   Thomas, Shane ^d   Russell, Elizabeth Anne ^a   Ooi, Sze Yuan ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Endothelin; Index of microvascular resistance; Peri procedural myocardial infarction; Trial design

Indexed keywords

AMBRISENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HUMAN; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MICROCIRCULATION; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; ACUTE CORONARY SYNDROME; ADOLESCENT; CORONARY ANGIOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DRUG EFFECTS; METABOLISM; MYOCARDIAL INFARCTION; PROCEDURES; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ACUTE CORONARY SYNDROME; ADOLESCENT; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY VESSELS; DOUBLE-BLIND METHOD; ENDOTHELIN A RECEPTOR ANTAGONISTS; HUMANS; MICROCIRCULATION; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RECEPTOR, ENDOTHELIN A; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84955560837     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-016-6641-x     Document Type: Article

References (49)

1. Thygesen K, Alpert J, Jaffe A, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–98.
2. Herrmann J Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005;26:2493–519.
3. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the society for cardiovascular angiography and interventions (SCAI). Cathet Cardiovasc Intervent. 2013;83:27–36.
4. Liou K, Jepson N, Kellar P, Ng B, Isbister J, Giles R, et al. Prognostic significance of peri-procedural myocardial infarction in the era of high sensitivity troponin: a validation of the joint ACCF/AHA/ESC/WHF universal definition of type 4a myocardial infarction with high sensitivity troponin T. Heart Lung Circ. 2015;24:673–81.
5. Liou K, Ng B, Isbister J, Kellar P, Jepson N, Pitney M, et al. Peri-procedural myocardial infarction following percutaneous coronary intervention as defined by the universal definition predicts increased mortality at 2 years. Int J Cardiol. 2015;199:96–8.
6. Leonardi S, Armstrong P, Schulte P, Ohman M, Newby L. Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J. 2013;34:894–902.
7. Mizuno O, Hojo Y, Ikeda U, Katsuki T-a, Fukazawa H, Kurosaki K et al. Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol. 85(2):154–160.
8. Ray MJ, Walters DL, Bett JNH, Cameron J, Wood P, Aroney CN. Platelet–monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab. Int J Cardiol. 101(2):249–255.
9. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010;3(6):602–10.
10. Petronio AS, Amoroso G, Limbruno U, Baglini R, Paterni G, Pinori E, et al. Endothelin-1 release from atherosclerotic plaque after percutaneous transluminal coronary angioplasty in Stable angina pectoris and single-vessel coronary artery disease. Am J Cardiol. 1999;84(9):1085–8.
11. Akdeniz C, Umman S, Nisanci Y, Umman B, Bugra Z, Aslanger E, et al. Percutaneous coronary intervention increases microvascular resistance in patients with non-ST-elevation acute coronary syndrome. EuroIntervention. 2013;9(2):228–34.
12. Layland JJ, Whitbourn RJ, Burns AT, Somaratne J, Leitl G, Macisaac AI, et al. The index of microvascular resistance identifies patients with periprocedural myocardial infarction in elective percutaneous coronary intervention. Heart. 2012;98(20):1492–7.
13. Payne AR, Berry C, Doolin O, McEntegart M, Petrie MC, Lindsay MM, et al. Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. J Am Heart Assoc. 2012;1:e002246.
14. Webb DJ. Endothelin: from molecule to man. Br J Clin Pharmacol. 1997;44:9–20.
15. Kyriakides ZS, Kremastinos DT, Bofilis E, Tousoulis D, Antoniadis A, Webb DJ. Endogenous endothelin maintains coronary artery tone by endothelin type a receptor stimulation in patients undergoing coronary arteriography. Heart. 2000;84(2):176–82.
16. Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995;114(6):1110–6.
17. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172(6):1741–8.
18. Hasdai D, Holmes DR, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circ. 1997;95(2):357–62.
19. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325(14):997–1001.
20. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun. 1993;191(3):1081–8.
21. Zeiher AM, Krause T, Schachinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 1995;91(9):2345–52.
22. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circ. 2001;104(10):1114–8.
23. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circ. 1998;98(21):2235–40.
24. Kruger D, Giannitsis E, Sheikhzadeh A, Stierle U. Cardiac release and kinetics of endothelin after uncomplicated percutaneous transluminal coronary angioplasty. Am J Cardiol. 1998;81(12):1421–6.
25. Suzuki H, Takeyama Y, Matsubara H, Hasegawa S, Hiroshige J, Murakami M, et al. Plasma endothelin-1 and thrombomodulin levels in coronary sinus during right atrial pacing and percutaneous transluminal coronary angioplasty. Int J Cardiol. 2000;74(1):15–23.
26. Katayama T, Yano K, Nakashima H, Takagi C, Honda Y, Suzuki S, et al. Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty. Circ J. 2005;69(6):654–8.
27. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty. Catheter Cardiovasc Interv. 2000;51(1):42–9.
28. Malatino LS, Grassi R, Stancanelli B, Polizzi G, Leonardi C, Tamburino C, et al. Release of immunoreactive endothelin from the heart during percutaneous transluminal coronary angioplasty. Am Heart J. 1993;126(3 Pt 1):700–2.
29. Eitel I, Nowak M, Stehl C, Adams V, Fuernau G, Hildebrand L, et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am Heart J. 2010;159(5):882–90.
30. Stewart DJKG, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38–43.
31. Wieczorek I, Haynes W, Webb D, Ludlam C, Fox K. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J. 1994;72(5):436–41.
32. Takahashi KKT, Takeda S, Sato K, Kanatsuka H, Shirato K. Nitric oxide inhibition unmasks ischaemic myocardium-derived vasoconstrictor signals activating endothelin type a receptor of coronary microvessels. Am J Physiol Heart Circ Physiol. 2005;289:H85–91.
33. Zouki CBC, Fournier A, Filep JG. Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(a) receptors and platelet-activating factor. Br J Pharmacol. 1999;127:969–79.
34. Gomez-Garre D, Guerra M, Gonzalez E, Lopez-Farre A, Riesco A, Escarnero J, et al. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor. Eur J Pharmacol. 1992;224:167–72.
35. Tamareille STM, Amirian J, Felli P, X.Q Z, W.H B, R.W S. Endothelin-1 Release during the Early Phase of Reperfusion Is a Mediator of Myocardial Reperfusion Injury. Cardiology. 2013;125:242–9.
36. Dong FZX, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323–33.
37. Colak MPH, Ermis N, Polat A, Colak C, Mizrak B, Ozdemir R, Acet A. The effect of selective endothelin receptor a antagonism by Bq-123 on myocardial ischemia-reperfusion induced apoptotic cell death. Med Sci. 2012;1(4):254–70.
38. Galron RBA, Kloog Y, Sokolovsky M. Endothelin/sarafotoxin receptor induced phosphoinositide turnover: effects of pertussis and cholera toxins and of phorbol esters. Biochem Biophys Res Commun. 1990;171:949–54.
39. Verma SFP. Weisel R; butany J; Rao V; Maitland a; Li, R, Dhillon B, Yau T. Fundamentals of reperfusion injury for the clinical cardiologist. Circ. 2002;105:2332–6.
40. Ikeda H, Toshima H, Nakayama H, Oda T, Kuwano K, Yamaga A, et al. Neutrophil activation after percutaneous transluminal coronary angioplasty. Am Heart J. 1994;128(6):1091–8.
41. Adlbrecht C, Andreas M, Redwan B, Distelmaier K, Mascherbauer J, Kaider A, et al. Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention. 2012;7(12):1386–95.
42. Frampton JE. Ambrisentan. Am J Cardiovasc Drugs. 2011;11(4):215–26.
43. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010–9.
44. Ng MKC, Yong ASC, Ho M, Shah MG, Chawantanpipat C, O’Connell R, et al. The index of microcirculatory resistance predicts myocardial infarction related to percutaneous coronary intervention. Circ Cardiovasc Interv. 2012;5:512–22.
45. Wong CX, Sun MT, Lau DH, Brooks AG, Sullivan T, Worthley MI, et al. Nationwide trends in the incidence of acute myocardial infarction in Australia, 1993–2010. Am J Cardiol. 2013;112:169–73.
46. McManus D, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg R. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med. 2011;124(1):40–7.
47. Ellis C, Hammett C, French J, Briffa T, Lefkovitz J, Ranasinghe I, et al. A comparison of invasive angiography, revascularisation and time delays delivered to Australian and New Zealand non-ST-elevation myocardial infarction/unstable angina pectoris (NSTEMI/UAP) patients: results of the 2012 SNAPSHOT bi-national acute coronary syndrome (ACS) audit. Heart Lung Circ. 2014;23:e3–e48.
48. Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy-thrombolysis in myocardial infarction. Circ. 2002;106(2):202–7.
49. Bolognese L, Ducci K, Angioli P, Falsini G, Liistro F, Baldassarre S, et al. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Circ. 2004;110(12):1592–7.